Rafferty Asset Management, LLC Arbutus Biopharma Corp Transaction History

Rafferty Asset Management, LLC

  • $26.7 Billion
  • Q1 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023
SELL
$2.23 - $3.1 $140,070 - $194,717
-62,812 Reduced 66.46%
31,693 $96,000
Q4 2022

Feb 13, 2023
BUY
$1.91 - $2.85 $76,736 - $114,501
40,176 Added 73.95%
94,505 $220,000
Q3 2022

Nov 14, 2022
SELL
$1.88 - $2.88 $25,205 - $38,612
-13,407 Reduced 19.79%
54,329 $104,000
Q2 2022

Aug 12, 2022
BUY
$1.98 - $3.17 $14,523 - $23,251
7,335 Added 12.14%
67,736 $184,000
Q1 2022

May 13, 2022
BUY
$2.42 - $3.98 $86,827 - $142,798
35,879 Added 146.31%
60,401 $180,000
Q4 2021

Feb 10, 2022
BUY
$3.11 - $4.61 $76,263 - $113,046
24,522 New
24,522 $95,000

Others Institutions Holding ABUS

# of Institutions
130
Shares Held
82.2M
Call Options Held
4.82M
Put Options Held
546K
View Full List

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $489M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email